Concepedia

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Kausik K. Ray, Roel P T Troquay, Frank L.J. Visseren, Lawrence A. Leiter, R. Scott Wright, Sheikh Vikarunnessa, Zsolt Talloczy, Xiao Zang, Pierre Maheux, Anastasia Lesogor,

The Lancet Diabetes & Endocrinology · 2023 · 282 citations · 23 references

DOIFull text

Open access

Abstract

Novartis Pharma.

References

23

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

François Mach, Colin Baigent, Alberico L. Catapano et al. · European Heart Journal · 2019 · 8.4K citations · Full text

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore, Ed Gane, Jörg Täubel et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray, R. Scott Wright, David Kallend et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Multivalent <i>N</i>-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Jayaprakash K. Nair, Jennifer L. S. Willoughby, Amy Chan et al. · Journal of the American Chemical Society · 2014 · 1K citations